Patricia Russo - Merck Independent Director

MRK Stock  USD 103.46  3.52  3.29%   

  Director

Ms. Patricia F. Russo is Independent Director of the Company. She is Lead Director, General Motors Company since 2010 and Director since 2009 Director, Alcoa Inc. since 2008 and HewlettPackard Company since 2011 . Ms. Russo was Chief Executive Officer and Director, AlcatelLucent from 2006 through 2008. She previously served as Chairman of Lucent Technologies Inc. from 2003 to 2006 and Chief Executive Officer and President from 2002 to 2006. Chairman, Partnership For a DrugFree America since 2010 Member, The Business Council, The Economic Club of New York and The Conference Board. since 1995.
Age: 68
Tenure: 28 years
Address: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Phone: 908 740 4000
Website: https://www.merck.com

Merck Management Efficiency

Merck Company has Return on Asset of 0.1268 % which means that on every $100 spent on asset, it made $0.1268 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.3815 %, implying that it generated $0.3815 on every 100 dollars invested. Merck management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Merck Return on Average Assets are increasing as compared to previous years. The last year's value of Return on Average Assets was reported at 11.91. The current Return on Average Equity is estimated to increase to 39.91, while Return on Investment is projected to decrease to 14.23. The current Tax Liabilities is estimated to increase to about 4.8 B, while Total Liabilities is projected to decrease to under 55.7 B.
The company has 30.69 B in debt with debt to equity (D/E) ratio of 0.68, which is OK given its current industry classification. Merck Company has a current ratio of 1.43, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Douglas RalphDelta Air Lines
62
Thomas DonilonDelta Air Lines
59
Lee BanksWestinghouse Air Brake
58
William EasterDelta Air Lines
71
Brian HehirWestinghouse Air Brake
67
Pascal DesrochesDaVita HealthCare Partners
55
Kenneth RogersDelta Air Lines
52
Paul DiazDaVita HealthCare Partners
58
Thomas LynchAutomatic Data Processing
N/A
Barbara DesoerDaVita HealthCare Partners
67
Shirley FranklinDelta Air Lines
69
Andrew StumpfAir T Inc
42
Nickolas SteegWestinghouse Air Brake
74
Seth BarkettAir T Inc
33
David DeWaltDelta Air Lines
56
Roger ValineDaVita HealthCare Partners
66
Robert HubbardAutomatic Data Processing
58
Jeanne JacksonDelta Air Lines
68
CHRISTOPHER HAZLETONDelta Air Lines
52
Mickey ForetDelta Air Lines
70
Michael GregoireAutomatic Data Processing
50
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. Merck Company (MRK) is traded on New York Stock Exchange in USA and employs 67,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification.

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Caroline Litchfield, Chief Financial Officer, Executive Vice President
Mirian GraddickWeir, Executive Vice President - Human Resources
Jannie Oosthuizen, Lead - Human Health U.S.
Jennifer Mauer, VP Communications
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Michael Klobuchar, Executive Vice President Chief Strategy Officer
Patricia Russo, Independent Director
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
William Harrison, Lead Independent Director
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Deepak Khanna, Lead - Human Health International
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Risa LavizzoMourey, Independent Director
Thomas Glocer, Lead Independent Director
Craig Thompson, Independent Director
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Arpa Garay, Lead - Human Health Global Marketing
Christine Seidman, Independent Director
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Stephen Mayo, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Peter Dannenbaum, VP Relations
Clark Golestani, CIO and Executive VP
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer
Robert JD, Pres Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Merck without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.29) 
Market Capitalization
272.3 B
Quarterly Revenue Growth
0.137
Return On Assets
0.1268
Return On Equity
0.3815
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.